Health care regulation organization Frier Levitt has analyzed FDA enforcement actions against “analysis only” peptide distributors. Their conclusion: the FDA considers an item’s classification based upon its intended use, not its disclaimers. When websites involve dosage guides, reconstitution instructions, or hyperlink to forums discussing h